Mylan N.V. (MYL)
Stock Price Chart
Key Info
| Market Cap | 8.46B |
| Revenue (ttm) | 11.50B |
| Net Income (ttm) | 270.50M |
| Shares Out | 516.95M |
| EPS (ttm) | 0.52 |
| PE Ratio | 31.46 |
| Forward PE | 3.81 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $16.36 |
| Previous Close | $16.42 |
| Change ($) | -0.06 |
| Change (%) | -0.37% |
| Day's Open | 16.21 |
| Day's Range | 16.01 - 16.42 |
| Day's Volume | 3,873,739 |
| 52-Week Range | 12.75 - 23.11 |
More Stats
| Market Cap | 8.46B |
| Enterprise Value | 20.33B |
| Earnings Date (est) | Nov 9, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 516.95M |
| Float | 513.55M |
| EPS (basic) | 0.53 |
| EPS (diluted) | 0.52 |
| FCF / Share | 3.18 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 3.18% |
| FCF Yield | 19.41% |
| Payout Ratio | n/a |
| Shares Short | 32.73M |
| Short Ratio | 5.69 |
| Short % of Float | 7.97% |
| Beta | 1.53 |
| PE Ratio | 31.46 |
| Forward PE | 3.81 |
| P/FCF Ratio | 5.15 |
| PS Ratio | 0.74 |
| PB Ratio | 0.75 |
| Revenue | 11.50B |
| Operating Income | 914.90M |
| Net Income | 270.50M |
| Free Cash Flow | 1.64B |
| Net Cash | -11.87B |
| Net Cash / Share | -22.96 |
| Gross Margin | 39.57% |
| Operating Margin | 7.95% |
| Profit Margin | 2.40% |
| FCF Margin | 14.27% |
| ROA | 3.49% |
| ROE | 2.29% |
| ROIC | 5.20% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,501 | 11,434 | 11,908 | 11,077 | 9,429 | 7,720 | 6,909 | 6,796 | 6,130 | 5,451 |
| Revenue Growth | 0.58% | -3.98% | 7.5% | 17.47% | 22.15% | 11.73% | 1.66% | 10.87% | 12.46% | - |
| Gross Profit | 3,898 | 4,002 | 4,783 | 4,697 | 4,216 | 3,528 | 3,040 | 2,908 | 2,563 | 2,217 |
| Operating Income | 716 | 906 | 1,437 | 699 | 1,461 | 1,353 | 1,136 | 1,109 | 1,005 | 722 |
| Net Income | 16.80 | 353 | 696 | 480 | 848 | 929 | 624 | 641 | 537 | 345 |
| Shares Outstanding | 516 | 515 | 535 | 513 | 472 | 374 | 383 | 415 | 431 | 324 |
| Earnings Per Share | 0.03 | 0.68 | 1.30 | 0.92 | 1.70 | 2.34 | 1.58 | 1.52 | 1.22 | 0.68 |
| EPS Growth | -95.59% | -47.69% | 41.3% | -45.88% | -27.35% | 48.1% | 3.95% | 24.59% | 79.41% | - |
| Operating Cash Flow | 1,804 | 2,342 | 2,065 | 2,047 | 2,009 | 1,015 | 1,107 | 949 | 720 | 931 |
| Capital Expenditures | -213 | -252 | -276 | -390 | -363 | -325 | -309 | -289 | -280 | -188 |
| Free Cash Flow | 1,591 | 2,090 | 1,789 | 1,657 | 1,646 | 690 | 797 | 660 | 441 | 744 |
| Cash & Equivalents | 476 | 388 | 292 | 999 | 1,236 | 226 | 291 | 350 | 375 | 715 |
| Total Debt | 12,722 | 13,863 | 14,721 | 15,539 | 7,374 | 8,504 | 8,030 | 5,734 | 5,299 | 5,433 |
| Net Cash / Debt | -12,247 | -13,475 | -14,429 | -14,541 | -6,138 | -8,278 | -7,739 | -5,384 | -4,924 | -4,718 |
| Assets | 31,256 | 32,735 | 35,806 | 34,726 | 22,268 | 15,821 | 15,295 | 11,932 | 11,598 | 11,537 |
| Liabilities | 19,372 | 20,568 | 22,499 | 23,609 | 12,502 | 12,545 | 12,335 | 8,576 | 8,093 | 7,921 |
| Book Value | 11,884 | 12,167 | 13,308 | 11,116 | 9,764 | 3,256 | 2,942 | 3,341 | 3,492 | 3,602 |
Company Profile
Company Details
| Full Name | Mylan N.V. |
| Country | United Kingdom |
| Employees | 35,000 |
| CEO | Heather M. Bresch |
Stock Information
| Ticker Symbol | MYL |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NASDAQ: MYL |
Description
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.